Eli Lilly (LLY) Total Debt (2009 - 2026)

Eli Lilly has reported Total Debt for 18 years, with the latest figure at $43.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Debt rose 12.6% year-over-year to $43.4 billion; the trailing twelve-month figure through Mar 2026 stood at $43.4 billion (up 12.6% YoY), and the FY2025 full-year result was $42.5 billion, up 26.33% from the prior year.
• Total Debt for Q1 2026 stood at $43.4 billion, up from $42.5 billion in the prior quarter.
• The five-year high for Total Debt was $43.4 billion in Q1 2026, with the low at $15.9 billion in Q3 2022.
• Historically, Total Debt has averaged $28.0 billion across 5 years, with a median of $26.2 billion in 2024.
• Annual changes were most pronounced in 2022 — Total Debt slipped 7.01% — and 2023, when it surged 55.34%.
• Eli Lilly's Total Debt stood at $16.2 billion in 2022, then surged by 55.34% to $25.2 billion in 2023, then soared by 33.37% to $33.6 billion in 2024, then advanced by 26.33% to $42.5 billion in 2025, then gained by 2.04% to $43.4 billion in 2026.
• The last three Total Debt figures came in at $43.4 billion (Q1 2026), $42.5 billion (Q4 2025), and $42.5 billion (Q3 2025), per Business Quant data.